Serina Therapeutics (Serina Therapeutics) Cash And Cash Equivalents : $8.71 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Cash And Cash Equivalents?

Serina Therapeutics's quarterly cash and cash equivalents increased from Dec. 2022 ($0.53 Mil) to Jun. 2023 ($8.72 Mil) but then stayed the same from Jun. 2023 ($8.72 Mil) to Mar. 2024 ($8.71 Mil).

Serina Therapeutics's annual cash and cash equivalents increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.32 Mil) and increased from Dec. 2021 ($0.32 Mil) to Dec. 2022 ($0.53 Mil).

Serina Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Serina Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Cash And Cash Equivalents Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

Cash And Cash Equivalents

0.32

0.53

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Mar24
Cash And Cash Equivalents	0.32	-	0.53	8.72	8.71

Serina Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Serina Therapeutics (AMEX:SER) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Serina Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

2BO:Germany

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024